Skip to content
Search

Latest Stories

RPS President: Pharmacists key to standardizing reproductive healthcare access, reducing inequalities

RPS President: Pharmacists key to standardizing reproductive healthcare access, reducing inequalities
RPS endorses call for improved women’s reproductive health by FSRH to Wes Streeting, Secretary of State for Health and Social Care

The Royal Pharmaceutical Society (RPS) has signed an open letter from Dr. Janet Barter, President of the Faculty of Sexual and Reproductive Health (FSRH), urging the Secretary of State for Health and Social Care to prioritise women's reproductive health.

Alongside 60 other organisations, including the National Pharmacy Association (NPA), the RPS has also highlighted the pressing issue of health inequalities across the country.


This action follows the 2023 launch of the FSRH’s Hatfield Vision and the recent release of the Hatfield Vision Manifesto, which the RPS supports.

The Manifesto outlines five key points, including the introduction of a dedicated Sexual and Reproductive Health Strategy and a commitment to continuing the Women's Health Strategy.

Additionally, it emphasises the need to improve access to a full range of contraceptives for all individuals at their preferred locations and to ensure that education and information about sexual and reproductive health are easily accessible throughout their lives.

The Manifesto also addresses racial health inequalities, stressing the importance of tackling the sexual and reproductive health disparities faced by Black women and women of color, and calls for the full funding of Community Sexual and Reproductive Health training posts.

"All women should have equal access to reproductive healthcare. Pharmacists play a crucial role in providing accessible healthcare, and standardizing access to reproductive healthcare will significantly benefit women and reduce health inequalities," Professor Claire Anderson, President of the RPS, stated.

"We hope the new government will work with us to ensure every individual can access the sexual and reproductive health services they need."

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less